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(GPI). Joint pain is frequently reported as the most egregious symptom.
However, though inﬂammation contributes to pain in RA, it may not
be the only factor. For some patients, pain does not improve despite
treatment with anti-inﬂammatory disease-modifying anti-rheumatic
drugs.
Systemic injection of type II collagen and GPI antibodies to mice induces
transient arthritis-like symptoms and joint pathology that resembles
human RA. While these models, called collagen-antibody induced
arthritis (CAIA) and K/BxN serum transfer arthritis (K/BxN) respectively,
are commonly used in the rheumatology ﬁeld, they have prior to our
work not been evaluated as models of arthritis-induced pain. Both
models generate pronounced pain-like behaviors such as mechanical
allodynia and reduced locomotor activity. Strikingly, the pain-like
behaviors occur not only during the inﬂammatory phase but outlast
the inﬂammation by at least four weeks. Of note, cyclooxygenase and
TNF inhibitors only have anti-nociceptive effect during the inﬂammatory
phase, while drugs like gabapentin reduce the hypersensitivity in
both phases, and pentoxifylline only reduces pain behavior during
the late phase, indicating that inﬂammatory and “post-inﬂammatory”
nociception are maintained through different mechanisms in these
models. This, taken together with the observation that ATF-3, a common
marker of nerve injury, is induced in dorsal root ganglia and that spinal
glia are activated in the late phase suggest that joint inﬂammation may
have a nerve damaging effect and that the persistent hypersensitivity
is driven at least in part by spinal sensitization. Interestingly, our
pharmacological and histological ﬁndings from the late phase of the CAIA
and K/BxN models show similarities with published data from animal
models of OA. Hence, our work suggest that a transient episode of joint
inﬂammation and/or joint damage may lead to long-term changes the
sensory system and it is possible that the late phase of the CAIA and
K/BxN models may be useful also for deciphering not only RA, but also
OA pain mechanisms. The aim of this presentation is to give a brief
overview of the physiology of OA pain, introduce the CAIA and K/BxN
models as new models of arthritis-induced pain and discuss similarities
and differences between RA and OA-induced pain from an experimental
point of view.
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GENETICS AND THE FUNCTIONAL ANALYSIS OF OA SUSCEPTIBILITY
LOCI
J. Loughlin. Newcastle Univ., Newcastle upon Tyne, United Kingdom
Genome-wide association scans are beginning to uncover novel
susceptibility loci for OA and these scans, combined with data from
some of the candidate gene based studies, are slowly enlightening our
understanding of the molecular genetic basis of this common arthritis.
Some of the discoveries are to genes whose proteins are known to have
roles in joint formation and maintenance whereas others are to genes
whose encoded proteins have less explicable roles in the articulating
joint. To exploit the genetic data for future use there is a need to
understand the impact OA susceptibility alleles are having on gene and
protein function and to understand how these alleles are themselves
modulated by, amongst other things, epigenetic regulation. This talk will
focus on the genetic and functional analysis of OA susceptibility and
present data on how our understanding of OA susceptibility is enhanced
when we advance from the purely genetic discoveries.
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ADHERENCE TO BEST PRACTICE IN THE CONSERVATIVE
MANAGEMENT OF OSTEOARTHRITIS
N.E. Foster. Keele Univ., Keele, United Kingdom
Peripheral joint osteoarthritis is a major cause of pain and functional
limitations in older adults in the community. Non-pharmacological
interventions play a key role in the holistic management of patients
with osteoarthritis. Advice and education about self-management,
exercise and physical activity, as well as weight loss, for example,
are consistent recommendations for clinical practice in national and
international guidelines [1,2]. These guidelines target patients, the
public and all health professionals involved in the care of this patient
population, including rheumatologists, family doctors, physical therapists
and others. This presentation will summarise best practice for patients
with osteoarthritis with a particular focus on non-pharmacological
interventions and examine the gap between best practice and current
practice, incorporating evidence about this gap from the perspectives of
patients and health care professionals. There are known barriers to the
adoption of best practice and whilst the key barriers will be discussed,
the presentation will focus on ways to improve the uptake of non-
pharmacological interventions in order to optimise patients’ outcomes.
This will include consideration of the potential drivers for change towards
adherence to best practice.
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INTRA-ARTICULAR INJECTION OF PURIFIED MESENCHYMAL STEM
CELLS FROM C57BL/6 OR MRL/MPJ “SUPERHEALER” MICE PREVENTS
POSTTRAUMATIC ARTHRITIS
B.O. Diekman, C-L. Wu, C.S. Louer, B.D. Furman, J.L. Huebner, V.B. Kraus,
S.A. Olson, F. Guilak. Duke Univ., Durham, NC, USA
Joint injury dramatically enhances the onset of osteoarthritis (OA) and
is responsible for an estimated 12% of OA. In particular, intra-articular
fracture is one of the greatest risk factors for the development of post-
traumatic arthritis (PTA); however, there are no therapeutic options
available that can alter the course of joint disease in this case. Using a
mouse model of PTA, the delivery of mesenchymal stem cells (MSCs)
to the joint was investigated to test the hypothesis that MSCs are
able to prevent PTA by altering the balance of inﬂammation and
regeneration after injury. Additionally, MSCs from c57BL/6 (B6) and
MRL/MpJ (MRL) mouse strains were compared, as MRL “superhealer”
mice have shown exceptional regenerative abilities. A pure population of
MSCs was prospectively isolated from bones using cell surface markers
(CD45-TER119-PDGFRa+Sca-1+). B6 MSCs expanded greater than 100,000
fold in three weeks when cultured at 2% oxygen and displayed greater
adipogenic, osteogenic, and chondrogenic differentiation as compared
to MRL MSCs. Mice receiving only a control saline injection after
fracture demonstrated signiﬁcant increase in cartilage degeneration after
8 weeks, but the delivery of 10,000 B6 or MRL MSCs to the joint was able
to prevent the development of PTA. MSC injection did not reduce the
degree of synovial inﬂammation but did show trends towards increasing
the bone volume during repair. This study provides evidence that adult
stem cell therapy can help prevent the development of PTA after fracture
and has implications for possible clinical interventions after joint injury
before evidence of signiﬁcant OA.
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HIP SHAPE AND OA: PREVENTION AND MANAGEMENT
Y-J. Kim. Children’s Hosp. Boston, Boston, MA, USA
Osteoarthritis of the hip is often due to underlying structural
abnormalities such as acetabular dysplasia, acetabular protrusio,
acetabular retroversion, or pistol grip deformity of the proximal femur.
Acetabular dysplasia is a shallowness of the acetabulum that leads to hip
instability and increased loading at the acetabular rim and osteoarthritis.
Acetabular protrusio, retroversion with or without a pistol grip deformity
of the proximal femur causes mechanical impingement, which may lead
to osteoarthritis. These mechanical causes of osteoarthritis were once
thought to be due to bony remodeling in response to osteoarthritis.
However, new evidence suggests that often these deformities preceed the
development of osteophyte and bony remodeling. Furthermore, some of
these hip deformities are highly prevalent in the general population and
may be an important risk factor for the development of osteoarthritis.
This talk will review the current available evidence that suggests these
structural variations are important as a cause of premature osteoarthritis,
as well as remaining controversies and needed future research. At
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present, both open and arthroscopic surgical treatment methods to
correct these deformities are advancing rapidly. Current state of the
art surgical treatment methods will be discussed as well as available
evidence demonstrating efﬁcacy of these treatment methods in relieving
symptoms as well as possibly affecting natural history of osteoarthritis
progression.
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OSTEOARTHRITIS YEAR IN REVIEW: REHABILITATION AND
OUTCOMES
A. Davis. Hlth.Care and Outcomes Res., Toronto Western Res. Inst., Toronto,
ON, Canada
Purpose: This review highlights seminal publications of rehabilitation
and outcomes in osteoarthritis of the hip or knee from the past year.
Methods:Medline, CINAHL, and Embase databases from September 2010
through June 2011 were searched using the key words ‘osteoarthritis’,
hip or knee, rehabilitation, physical therapy, exercise, and outcome(s),
limited to human and English. Studies of surgical interventions
were excluded unless they included evaluation of a rehabilitation
intervention. Rehabilitation intervention studies were included if they
were randomized trials or systematic reviews/meta-analyses and studies
related to outcomes were included if they contributed methodologically
to advancing outcome measurement. A total of 10 publications were
reviewed that thematically relate to interventions evaluating manual
therapy in hip or knee OA, tele-rehabilitation and performance measures
and participation as outcomes.
Results: Interventions: One systematic review of hip and knee OA, one
meta-analysis of knee OA and one additional small study of hip OA
provide limited support for the beneﬁt of manual therapy with exercise
for improving pain in the short term (three months). However, study
quality is low due to lack of blinding and disclosure of co-intervention.
One RCT in knee replacement of usual outpatient physiotherapy versus
internet-based tele-rehabilitation based on a non-inferiority analysis
demonstrated comparable outcomes on pain and performance measures.
The tele-rehabilitation group had improved outcomes in WOMAC
function and stiffness.
Outcomes: Three studies demonstrated that observed performance
measures such as timed walk tests and stair-climbing and timed-up-
and-go measure concepts different from self-report of difﬁculty with
physical function. Additionally, one study showed differential times of
recovery following TKR.
Two studies evaluated participation. One demonstrated the conceptual
distinction of activity limitations and participation and a second re-
analyzed trial data from knee OA and back pain studies demonstrating
larger effects in participation for arthroscopic lavage and physiotherapy
interventions than for activity.
Conclusions: Interventions of manual therapy for hip and knee OA
provided limited evidence of effectiveness. These studies are of limited
quality due to lack of blinding and disclosure of co-intervention. Tele-
rehabilitation may be a viable option to improve access to rehabilitation
post joint replacement for those in rural and remote areas.
Data continue to support the need to include performance measures
as well as patient-reported outcomes in evaluating outcomes in OA.
Additionally, measures of participation need to be included as core
outcomes.
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OSTEOARTHRITIS YEAR IN REVIEW: BIOMARKERS
Y. Henrotin. Univ. of Liege, Liege, Belgium
Purpose: This lecture is a summary of the published studies, ongoing
researches, initiatives and consensus building during last 12 months in
the ﬁeld of biochemical markers.
Methods: To select OA biomarker studies for this year in review, I
performed a systematic search in the pubmed database limited to the
prior 12 months using the query terms OA and biomarkers and reviewed
the abstracts of the 2011 OARSI World congress.
Results: This year was dominated by the publication of the OARSI/FDA
white paper on the “Application of biomarkers in the development of
drug intended for the treatment of osteoarthritis”. This white paper
contains responses to queries posed by the FDA in an effort to consider
revision of guidelines for drug development, recommendations on
biomarkers qualiﬁcation, a summary of the critical needs in the OA
biomarker ﬁeld and an agenda of research to advance the science
of OA-related biomarkers. Another signiﬁcant occurrence of this year
was the identiﬁcation by proteomic technics of a great number of new
potential biomarkers. Among these new biochemical markers, there are
ﬁbulin-3 fragments (Fib3–1 and Fib3–2), V65 vitronectin fragment, C3f
peptide, Cartilage Acidic protein-1 or cathepsin generated fragments
of C-reactive protein. Finally, D-COMP, a unique deaminated cartilage
oligomeric matrix protein (COMP), was the ﬁrst biomarker to show
speciﬁcity for hip osteoarthritis.
Conclusions: The last 12 months were marked by the emergence of a
large number a new biomarkers which need to be qualiﬁed in large
cohortes in the respect of the recommendations published by the
OARSI/FDA working group.
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OSTEOARTHRITIS YEAR IN REVIEW 2011: IMAGING
A. Guermazi. Boston Univ. Sch. of Med., Boston, MA, USA
Application of imaging is increasingly playing an important role in
osteoarthritis (OA) research. Currently, radiography, MRI and ultrasound
are commonly used as an imaging tool. MRI assessment of OA features
can be morphologic or functional. Morphologic assessment includes
semiquantitative and quantitative analysis and research efforts are
actively ongoing using both methods. Several scoring systems already
exist, but new semiquantitative scoring methods for knee and hip
OA using MRI were developed in addition. The OARSI OA imaging
working group published a series of key reports this year, reviewing the
importance of radiography and MRI as a research tool. Although recent
research efforts have discovered that radiography is relatively insensitive
for detection of OA pathology compared to MRI, we had no choice but
to use the radiographic deﬁnition of OA in clinical trials because of a
lack of MRI deﬁnition of OA and FDA-approved endpoints based on MRI
ﬁndings. In an attempt to alleviate this problem, a Delphi exercise was
performed to develop a testable MRI deﬁnition of structural OA and
its results were published. This presentation reviews the publications
related to imaging of OA, published in English between December 2010
and September 2011, excluding preclinical or in vitro data. This is not a
systematic review and the selection of papers included is based on the
expert opinions of the presenter, from a musculoskeletal radiologist’s
perspective.
